View Future GrowthInnospec 過去の業績過去 基準チェック /46Innospecの収益は年間平均-3.8%の割合で減少していますが、 Chemicals業界の収益は年間 増加しています。収益は年間3% 5.2%割合で 増加しています。 Innospecの自己資本利益率は8.4%であり、純利益率は6.4%です。主要情報-3.83%収益成長率-4.02%EPS成長率Chemicals 業界の成長4.35%収益成長率5.18%株主資本利益率8.42%ネット・マージン6.38%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 08First quarter 2026 earnings released: EPS: US$1.23 (vs US$1.31 in 1Q 2025)First quarter 2026 results: EPS: US$1.23 (down from US$1.31 in 1Q 2025). Revenue: US$453.2m (up 2.8% from 1Q 2025). Net income: US$30.4m (down 7.3% from 1Q 2025). Profit margin: 6.7% (down from 7.4% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 7.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.お知らせ • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026Reported Earnings • Feb 18Full year 2025 earnings released: EPS: US$4.69 (vs US$1.43 in FY 2024)Full year 2025 results: EPS: US$4.69 (up from US$1.43 in FY 2024). Revenue: US$1.78b (down 3.7% from FY 2024). Net income: US$116.6m (up 228% from FY 2024). Profit margin: 6.6% (up from 1.9% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 13% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Jan 12Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.52 (vs US$1.34 in 3Q 2024)Third quarter 2025 results: EPS: US$0.52 (down from US$1.34 in 3Q 2024). Revenue: US$441.9m (flat on 3Q 2024). Net income: US$12.9m (down 61% from 3Q 2024). Profit margin: 2.9% (down from 7.5% in 3Q 2024). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.お知らせ • Oct 02Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025すべての更新を表示Recent updatesDeclared Dividend • May 17Dividend of US$0.92 announcedShareholders will receive a dividend of US$0.92. Ex-date: 19th May 2026 Payment date: 29th May 2026 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (37% earnings payout ratio) and cash flows (80% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 15% over the next year, which should provide support to the dividend and adequate earnings cover.お知らせ • May 10Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026.お知らせ • May 08Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock.Reported Earnings • May 08First quarter 2026 earnings released: EPS: US$1.23 (vs US$1.31 in 1Q 2025)First quarter 2026 results: EPS: US$1.23 (down from US$1.31 in 1Q 2025). Revenue: US$453.2m (up 2.8% from 1Q 2025). Net income: US$30.4m (down 7.3% from 1Q 2025). Profit margin: 6.7% (down from 7.4% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 7.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.お知らせ • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026お知らせ • Mar 27Innospec Inc., Annual General Meeting, May 08, 2026Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United StatesReported Earnings • Feb 18Full year 2025 earnings released: EPS: US$4.69 (vs US$1.43 in FY 2024)Full year 2025 results: EPS: US$4.69 (up from US$1.43 in FY 2024). Revenue: US$1.78b (down 3.7% from FY 2024). Net income: US$116.6m (up 228% from FY 2024). Profit margin: 6.6% (up from 1.9% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 13% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Jan 12Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026Board Change • Jan 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Declared Dividend • Nov 08Dividend of US$0.87 announcedShareholders will receive a dividend of US$0.87. Ex-date: 18th November 2025 Payment date: 26th November 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.52 (vs US$1.34 in 3Q 2024)Third quarter 2025 results: EPS: US$0.52 (down from US$1.34 in 3Q 2024). Revenue: US$441.9m (flat on 3Q 2024). Net income: US$12.9m (down 61% from 3Q 2024). Profit margin: 2.9% (down from 7.5% in 3Q 2024). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.お知らせ • Nov 05Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2025, Payable on November 26, 2025Innospec Inc. declared a semi-annual dividend of 87 cents per common share for the second half of 2025, which will be paid on November 26, 2025 to shareholders of record as of November 18, 2025.Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 02Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025Board Change • Sep 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 06Second quarter 2025 earnings released: EPS: US$0.94 (vs US$1.25 in 2Q 2024)Second quarter 2025 results: EPS: US$0.94 (down from US$1.25 in 2Q 2024). Revenue: US$439.7m (up 1.1% from 2Q 2024). Net income: US$23.5m (down 25% from 2Q 2024). Profit margin: 5.3% (down from 7.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.お知らせ • Jul 03Innospec Inc. to Report Q2, 2025 Results on Aug 05, 2025Innospec Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025Board Change • Jun 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Declared Dividend • May 19Dividend of US$0.84 announcedShareholders will receive a dividend of US$0.84. Ex-date: 20th May 2025 Payment date: 30th May 2025 Dividend yield will be 1.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (143% earnings payout ratio). However, it is covered by cash flows (57% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 59% to bring the payout ratio under control. EPS is expected to grow by 65% over the next year, which is sufficient to bring the dividend into a sustainable range.Board Change • May 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 09Innospec Inc. Declares Semi-Annual Dividend, Payable on May 30, 2025Innospec Inc. declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 30, 2025 to shareholders of record on May 20, 2025.Buy Or Sell Opportunity • Apr 10Now 24% overvaluedThe stock has been flat over the last 90 days, currently trading at US$85.47. The fair value is estimated to be US$68.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 10.0% in 2 years. Earnings are forecast to grow by 345% in the next 2 years.お知らせ • Apr 04Innospec Inc. to Report Q1, 2025 Results on May 08, 2025Innospec Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025お知らせ • Mar 28Innospec Inc., Annual General Meeting, May 09, 2025Innospec Inc., Annual General Meeting, May 09, 2025. Location: westin at the woodlands hotel, 2 waterway square place, the woodlands, houston tx 77380, United StatesBoard Change • Mar 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 11Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock.Recent Insider Transactions • Mar 09Executive VP & CFO recently sold US$432k worth of stockOn the 3rd of March, Ian Cleminson sold around 4k shares on-market at roughly US$101 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.6m.Recent Insider Transactions • Feb 26COO & Executive VP recently sold US$388k worth of stockOn the 21st of February, Philip Boon sold around 4k shares on-market at roughly US$103 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Philip's only on-market trade for the last 12 months.New Risk • Feb 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 7.2% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.9% net profit margin).Reported Earnings • Feb 19Full year 2024 earnings released: EPS: US$1.43 (vs US$5.60 in FY 2023)Full year 2024 results: EPS: US$1.43 (down from US$5.60 in FY 2023). Revenue: US$1.85b (down 5.3% from FY 2023). Net income: US$35.6m (down 74% from FY 2023). Profit margin: 1.9% (down from 7.1% in FY 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 2 years, compared to a 4.0% decline forecast for the Chemicals industry in the United Kingdom.Board Change • Jan 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jan 09Innospec Inc. to Report Q4, 2024 Results on Feb 18, 2025Innospec Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025Declared Dividend • Nov 11Dividend of US$0.79 announcedShareholders will receive a dividend of US$0.79. Ex-date: 18th November 2024 Payment date: 26th November 2024 Dividend yield will be 1.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 2 years, which should provide support to the dividend and adequate earnings cover.New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Significant insider selling over the past 3 months (US$1.1m sold).Reported Earnings • Nov 06Third quarter 2024 earnings released: EPS: US$1.34 (vs US$1.58 in 3Q 2023)Third quarter 2024 results: EPS: US$1.34 (down from US$1.58 in 3Q 2023). Revenue: US$443.4m (down 4.5% from 3Q 2023). Net income: US$33.4m (down 15% from 3Q 2023). Profit margin: 7.5% (down from 8.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.8% p.a. on average during the next 2 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.お知らせ • Oct 04Innospec Inc. to Report Q3, 2024 Results on Nov 06, 2024Innospec Inc. announced that they will report Q3, 2024 results on Nov 06, 2024Recent Insider Transactions • Aug 29Executive VP & CFO recently sold US$1.1m worth of stockOn the 26th of August, Ian Cleminson sold around 10k shares on-market at roughly US$114 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.7m.Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: US$1.25 (vs US$1.16 in 2Q 2023)Second quarter 2024 results: EPS: US$1.25 (up from US$1.16 in 2Q 2023). Revenue: US$435.0m (down 9.5% from 2Q 2023). Net income: US$31.2m (up 8.0% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Jul 17Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to US$132. The fair value is estimated to be US$107, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.0% in a year. Earnings are forecast to grow by 11% in the next year.お知らせ • Jul 04Innospec Inc. to Report Q2, 2024 Results on Aug 06, 2024Innospec Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024お知らせ • May 11Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2024Innospec Inc. declared its semi-annual dividend of 76 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 31, 2024 to shareholders of record on May 20, 2024.Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.34 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.34 in 1Q 2023). Revenue: US$500.2m (down 1.8% from 1Q 2023). Net income: US$41.4m (up 25% from 1Q 2023). Profit margin: 8.3% (up from 6.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.お知らせ • Apr 06Innospec Inc. to Report Q1, 2024 Results on May 09, 2024Innospec Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024お知らせ • Apr 03Innospec Inc. Announces Retirement of Philip Boon, Executive Vice President and Chief Operating Officer Effective March 31, 2025On March 31, 2024, Dr. Philip Boon, Executive Vice President and Chief Operating Officer of Innospec Inc. (the “Company”), informed the Company of his decision to officially retire effective March 31, 2025. Dr. Boon will provide various support to the Company on a consultancy basis, on terms to be agreed, after his retirement.お知らせ • Mar 29Innospec Inc., Annual General Meeting, May 10, 2024Innospec Inc., Annual General Meeting, May 10, 2024, at 10:00 US Eastern Standard Time. Location: The offices of Smith, Gambrell & Russell LLP 1105 West Peachtree Street NE suite 1000 Atlanta Georgia United States Agenda: To consider election of two Class II Directors; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm; and to discuss other matters.Recent Insider Transactions • Feb 28President recently sold US$1.2m worth of stockOn the 23rd of February, Patrick Williams sold around 10k shares on-market at roughly US$124 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Patrick has been a net seller over the last 12 months, reducing personal holdings by US$4.3m.Reported Earnings • Feb 14Full year 2023 earnings released: EPS: US$5.60 (vs US$5.37 in FY 2022)Full year 2023 results: EPS: US$5.60 (up from US$5.37 in FY 2022). Revenue: US$1.95b (flat on FY 2022). Net income: US$139.1m (up 4.6% from FY 2022). Profit margin: 7.1% (up from 6.8% in FY 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 2 years, compared to a 4.4% decline forecast for the Chemicals industry in the United Kingdom.Board Change • Dec 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Dec 12Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A.Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. on December 8, 2023. Innospec will integrate QGP into its Performance Chemicals business. Innospec Inc. (NasdaqGS:IOSP) completed the acquisition of QGP Química Geral S.A. on December 8, 2023.Board Change • Dec 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 10Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.56 in 3Q 2022)Third quarter 2023 results: EPS: US$1.58 (up from US$1.56 in 3Q 2022). Revenue: US$464.1m (down 9.5% from 3Q 2022). Net income: US$39.2m (up 1.3% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 08Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2023, Payable on November 27, 2023Innospec Inc. announced that it has declared a semi-annual dividend of 72 cents per common share for the second half of 2023 which will be paid on November 27, 2023 to shareholders of record as of November 20, 2023. This brings the annual dividend to $1.41 per share, a 10 percent increase over 2022.お知らせ • Aug 13Innospec Inc. to Report Q3, 2023 Results on Nov 07, 2023Innospec Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 07, 2023お知らせ • Jul 07Innospec Inc. to Report Q2, 2023 Results on Aug 08, 2023Innospec Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023Upcoming Dividend • May 12Upcoming dividend of US$0.69 per share at 1.4% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.3%).Reported Earnings • May 05First quarter 2023 earnings released: EPS: US$1.34 (vs US$1.47 in 1Q 2022)First quarter 2023 results: EPS: US$1.34 (down from US$1.47 in 1Q 2022). Revenue: US$509.6m (up 7.9% from 1Q 2022). Net income: US$33.2m (down 9.0% from 1Q 2022). Profit margin: 6.5% (down from 7.7% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.3% p.a. on average during the next 2 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.お知らせ • May 05Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2023Innospec Inc. declared a semi-annual dividend of $0.69 per share on the Company’s common stock (IOSP). The dividend will be paid on May 31, 2023 to holders of record on May 22, 2023.Recent Insider Transactions • Mar 04President recently sold US$2.0m worth of stockOn the 28th of February, Patrick Williams sold around 18k shares on-market at roughly US$111 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months.Reported Earnings • Feb 23Full year 2022 earnings released: EPS: US$5.37 (vs US$3.78 in FY 2021)Full year 2022 results: EPS: US$5.37 (up from US$3.78 in FY 2021). Revenue: US$1.96b (up 32% from FY 2021). Net income: US$133.0m (up 43% from FY 2021). Profit margin: 6.8% (up from 6.3% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom.お知らせ • Jan 11Innospec Inc. to Report Q4, 2022 Results on Feb 21, 2023Innospec Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2023収支内訳Innospec の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史LSE:0JAX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 261,7901142955231 Dec 251,7781172855130 Sep 251,789-13014630 Jun 251,791192924631 Mar 251,786272795531 Dec 241,845362985730 Sep 241,8731443225130 Jun 241,8941503414931 Mar 241,9391473754531 Dec 231,9491393744930 Sep 231,9651273764130 Jun 232,0141263894031 Mar 232,0011303673931 Dec 221,9641333563930 Sep 221,8661313294030 Jun 221,7291163044031 Mar 221,6161062833931 Dec 211,483932623730 Sep 211,381922473430 Jun 211,270812303231 Mar 211,160192313131 Dec 201,193292373130 Sep 201,273372423330 Jun 201,380552593531 Mar 201,4971172663531 Dec 191,5131122743530 Sep 191,5181022713530 Jun 191,509922653431 Mar 191,505922603431 Dec 181,477852553330 Sep 181,436602563330 Jun 181,405632543331 Mar 181,373672503231 Dec 171,307622403130 Sep 171,191892333030 Jun 171,064772292831 Mar 17966802212631 Dec 16883812102530 Sep 16892912082630 Jun 169401152052631 Mar 169551212022631 Dec 151,0121202072530 Sep 151,0571161992430 Jun 151,03110118824質の高い収益: 0JAXは 高品質の収益 を持っています。利益率の向上: 0JAXの現在の純利益率 (6.4%)は、昨年(1.5%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 0JAXの収益は過去 5 年間で年間3.8%減少しました。成長の加速: 0JAXの過去 1 年間の収益成長率 ( 323% ) は、5 年間の平均 ( 年間-3.8%を上回っています。収益対業界: 0JAXの過去 1 年間の収益成長率 ( 323% ) はChemicals業界-59.9%を上回りました。株主資本利益率高いROE: 0JAXの 自己資本利益率 ( 8.4% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 22:53終値2026/05/27 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Innospec Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Jonathan TanwantengCJS Securities, Inc.David SilverFreedom Capital MarketsSean MilliganJohnson Rice & Company, L.L.C.4 その他のアナリストを表示
Reported Earnings • May 08First quarter 2026 earnings released: EPS: US$1.23 (vs US$1.31 in 1Q 2025)First quarter 2026 results: EPS: US$1.23 (down from US$1.31 in 1Q 2025). Revenue: US$453.2m (up 2.8% from 1Q 2025). Net income: US$30.4m (down 7.3% from 1Q 2025). Profit margin: 6.7% (down from 7.4% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 7.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026
Reported Earnings • Feb 18Full year 2025 earnings released: EPS: US$4.69 (vs US$1.43 in FY 2024)Full year 2025 results: EPS: US$4.69 (up from US$1.43 in FY 2024). Revenue: US$1.78b (down 3.7% from FY 2024). Net income: US$116.6m (up 228% from FY 2024). Profit margin: 6.6% (up from 1.9% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 13% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 12Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026
Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.52 (vs US$1.34 in 3Q 2024)Third quarter 2025 results: EPS: US$0.52 (down from US$1.34 in 3Q 2024). Revenue: US$441.9m (flat on 3Q 2024). Net income: US$12.9m (down 61% from 3Q 2024). Profit margin: 2.9% (down from 7.5% in 3Q 2024). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 02Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025
Declared Dividend • May 17Dividend of US$0.92 announcedShareholders will receive a dividend of US$0.92. Ex-date: 19th May 2026 Payment date: 29th May 2026 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (37% earnings payout ratio) and cash flows (80% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 15% over the next year, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 10Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026.
お知らせ • May 08Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock.
Reported Earnings • May 08First quarter 2026 earnings released: EPS: US$1.23 (vs US$1.31 in 1Q 2025)First quarter 2026 results: EPS: US$1.23 (down from US$1.31 in 1Q 2025). Revenue: US$453.2m (up 2.8% from 1Q 2025). Net income: US$30.4m (down 7.3% from 1Q 2025). Profit margin: 6.7% (down from 7.4% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 7.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026
お知らせ • Mar 27Innospec Inc., Annual General Meeting, May 08, 2026Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United States
Reported Earnings • Feb 18Full year 2025 earnings released: EPS: US$4.69 (vs US$1.43 in FY 2024)Full year 2025 results: EPS: US$4.69 (up from US$1.43 in FY 2024). Revenue: US$1.78b (down 3.7% from FY 2024). Net income: US$116.6m (up 228% from FY 2024). Profit margin: 6.6% (up from 1.9% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 13% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 12Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026
Board Change • Jan 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Declared Dividend • Nov 08Dividend of US$0.87 announcedShareholders will receive a dividend of US$0.87. Ex-date: 18th November 2025 Payment date: 26th November 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.
Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.52 (vs US$1.34 in 3Q 2024)Third quarter 2025 results: EPS: US$0.52 (down from US$1.34 in 3Q 2024). Revenue: US$441.9m (flat on 3Q 2024). Net income: US$12.9m (down 61% from 3Q 2024). Profit margin: 2.9% (down from 7.5% in 3Q 2024). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 05Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2025, Payable on November 26, 2025Innospec Inc. declared a semi-annual dividend of 87 cents per common share for the second half of 2025, which will be paid on November 26, 2025 to shareholders of record as of November 18, 2025.
Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 02Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025
Board Change • Sep 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 06Second quarter 2025 earnings released: EPS: US$0.94 (vs US$1.25 in 2Q 2024)Second quarter 2025 results: EPS: US$0.94 (down from US$1.25 in 2Q 2024). Revenue: US$439.7m (up 1.1% from 2Q 2024). Net income: US$23.5m (down 25% from 2Q 2024). Profit margin: 5.3% (down from 7.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • Jul 03Innospec Inc. to Report Q2, 2025 Results on Aug 05, 2025Innospec Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025
Board Change • Jun 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Declared Dividend • May 19Dividend of US$0.84 announcedShareholders will receive a dividend of US$0.84. Ex-date: 20th May 2025 Payment date: 30th May 2025 Dividend yield will be 1.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (143% earnings payout ratio). However, it is covered by cash flows (57% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 59% to bring the payout ratio under control. EPS is expected to grow by 65% over the next year, which is sufficient to bring the dividend into a sustainable range.
Board Change • May 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 09Innospec Inc. Declares Semi-Annual Dividend, Payable on May 30, 2025Innospec Inc. declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 30, 2025 to shareholders of record on May 20, 2025.
Buy Or Sell Opportunity • Apr 10Now 24% overvaluedThe stock has been flat over the last 90 days, currently trading at US$85.47. The fair value is estimated to be US$68.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 10.0% in 2 years. Earnings are forecast to grow by 345% in the next 2 years.
お知らせ • Apr 04Innospec Inc. to Report Q1, 2025 Results on May 08, 2025Innospec Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025
お知らせ • Mar 28Innospec Inc., Annual General Meeting, May 09, 2025Innospec Inc., Annual General Meeting, May 09, 2025. Location: westin at the woodlands hotel, 2 waterway square place, the woodlands, houston tx 77380, United States
Board Change • Mar 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 11Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock.
Recent Insider Transactions • Mar 09Executive VP & CFO recently sold US$432k worth of stockOn the 3rd of March, Ian Cleminson sold around 4k shares on-market at roughly US$101 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.6m.
Recent Insider Transactions • Feb 26COO & Executive VP recently sold US$388k worth of stockOn the 21st of February, Philip Boon sold around 4k shares on-market at roughly US$103 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Philip's only on-market trade for the last 12 months.
New Risk • Feb 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 7.2% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.9% net profit margin).
Reported Earnings • Feb 19Full year 2024 earnings released: EPS: US$1.43 (vs US$5.60 in FY 2023)Full year 2024 results: EPS: US$1.43 (down from US$5.60 in FY 2023). Revenue: US$1.85b (down 5.3% from FY 2023). Net income: US$35.6m (down 74% from FY 2023). Profit margin: 1.9% (down from 7.1% in FY 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 2 years, compared to a 4.0% decline forecast for the Chemicals industry in the United Kingdom.
Board Change • Jan 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jan 09Innospec Inc. to Report Q4, 2024 Results on Feb 18, 2025Innospec Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025
Declared Dividend • Nov 11Dividend of US$0.79 announcedShareholders will receive a dividend of US$0.79. Ex-date: 18th November 2024 Payment date: 26th November 2024 Dividend yield will be 1.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Significant insider selling over the past 3 months (US$1.1m sold).
Reported Earnings • Nov 06Third quarter 2024 earnings released: EPS: US$1.34 (vs US$1.58 in 3Q 2023)Third quarter 2024 results: EPS: US$1.34 (down from US$1.58 in 3Q 2023). Revenue: US$443.4m (down 4.5% from 3Q 2023). Net income: US$33.4m (down 15% from 3Q 2023). Profit margin: 7.5% (down from 8.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.8% p.a. on average during the next 2 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.
お知らせ • Oct 04Innospec Inc. to Report Q3, 2024 Results on Nov 06, 2024Innospec Inc. announced that they will report Q3, 2024 results on Nov 06, 2024
Recent Insider Transactions • Aug 29Executive VP & CFO recently sold US$1.1m worth of stockOn the 26th of August, Ian Cleminson sold around 10k shares on-market at roughly US$114 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.7m.
Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: US$1.25 (vs US$1.16 in 2Q 2023)Second quarter 2024 results: EPS: US$1.25 (up from US$1.16 in 2Q 2023). Revenue: US$435.0m (down 9.5% from 2Q 2023). Net income: US$31.2m (up 8.0% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Jul 17Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to US$132. The fair value is estimated to be US$107, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.0% in a year. Earnings are forecast to grow by 11% in the next year.
お知らせ • Jul 04Innospec Inc. to Report Q2, 2024 Results on Aug 06, 2024Innospec Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024
お知らせ • May 11Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2024Innospec Inc. declared its semi-annual dividend of 76 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 31, 2024 to shareholders of record on May 20, 2024.
Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.34 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.34 in 1Q 2023). Revenue: US$500.2m (down 1.8% from 1Q 2023). Net income: US$41.4m (up 25% from 1Q 2023). Profit margin: 8.3% (up from 6.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.
お知らせ • Apr 06Innospec Inc. to Report Q1, 2024 Results on May 09, 2024Innospec Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024
お知らせ • Apr 03Innospec Inc. Announces Retirement of Philip Boon, Executive Vice President and Chief Operating Officer Effective March 31, 2025On March 31, 2024, Dr. Philip Boon, Executive Vice President and Chief Operating Officer of Innospec Inc. (the “Company”), informed the Company of his decision to officially retire effective March 31, 2025. Dr. Boon will provide various support to the Company on a consultancy basis, on terms to be agreed, after his retirement.
お知らせ • Mar 29Innospec Inc., Annual General Meeting, May 10, 2024Innospec Inc., Annual General Meeting, May 10, 2024, at 10:00 US Eastern Standard Time. Location: The offices of Smith, Gambrell & Russell LLP 1105 West Peachtree Street NE suite 1000 Atlanta Georgia United States Agenda: To consider election of two Class II Directors; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm; and to discuss other matters.
Recent Insider Transactions • Feb 28President recently sold US$1.2m worth of stockOn the 23rd of February, Patrick Williams sold around 10k shares on-market at roughly US$124 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Patrick has been a net seller over the last 12 months, reducing personal holdings by US$4.3m.
Reported Earnings • Feb 14Full year 2023 earnings released: EPS: US$5.60 (vs US$5.37 in FY 2022)Full year 2023 results: EPS: US$5.60 (up from US$5.37 in FY 2022). Revenue: US$1.95b (flat on FY 2022). Net income: US$139.1m (up 4.6% from FY 2022). Profit margin: 7.1% (up from 6.8% in FY 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 2 years, compared to a 4.4% decline forecast for the Chemicals industry in the United Kingdom.
Board Change • Dec 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 12Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A.Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. on December 8, 2023. Innospec will integrate QGP into its Performance Chemicals business. Innospec Inc. (NasdaqGS:IOSP) completed the acquisition of QGP Química Geral S.A. on December 8, 2023.
Board Change • Dec 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 10Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.56 in 3Q 2022)Third quarter 2023 results: EPS: US$1.58 (up from US$1.56 in 3Q 2022). Revenue: US$464.1m (down 9.5% from 3Q 2022). Net income: US$39.2m (up 1.3% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 08Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2023, Payable on November 27, 2023Innospec Inc. announced that it has declared a semi-annual dividend of 72 cents per common share for the second half of 2023 which will be paid on November 27, 2023 to shareholders of record as of November 20, 2023. This brings the annual dividend to $1.41 per share, a 10 percent increase over 2022.
お知らせ • Aug 13Innospec Inc. to Report Q3, 2023 Results on Nov 07, 2023Innospec Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 07, 2023
お知らせ • Jul 07Innospec Inc. to Report Q2, 2023 Results on Aug 08, 2023Innospec Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023
Upcoming Dividend • May 12Upcoming dividend of US$0.69 per share at 1.4% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.3%).
Reported Earnings • May 05First quarter 2023 earnings released: EPS: US$1.34 (vs US$1.47 in 1Q 2022)First quarter 2023 results: EPS: US$1.34 (down from US$1.47 in 1Q 2022). Revenue: US$509.6m (up 7.9% from 1Q 2022). Net income: US$33.2m (down 9.0% from 1Q 2022). Profit margin: 6.5% (down from 7.7% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.3% p.a. on average during the next 2 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.
お知らせ • May 05Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2023Innospec Inc. declared a semi-annual dividend of $0.69 per share on the Company’s common stock (IOSP). The dividend will be paid on May 31, 2023 to holders of record on May 22, 2023.
Recent Insider Transactions • Mar 04President recently sold US$2.0m worth of stockOn the 28th of February, Patrick Williams sold around 18k shares on-market at roughly US$111 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months.
Reported Earnings • Feb 23Full year 2022 earnings released: EPS: US$5.37 (vs US$3.78 in FY 2021)Full year 2022 results: EPS: US$5.37 (up from US$3.78 in FY 2021). Revenue: US$1.96b (up 32% from FY 2021). Net income: US$133.0m (up 43% from FY 2021). Profit margin: 6.8% (up from 6.3% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom.
お知らせ • Jan 11Innospec Inc. to Report Q4, 2022 Results on Feb 21, 2023Innospec Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2023